AroCell AB (publ)

As of March 31, 2025, AroCell AB (publ) has 230.36M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 2.17, and the price-to-book ratio stands at -0.39.

These figures are as of March 31, 2025. The EV/Sales ratio of 1.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. AroCell AB (publ) trades at an EV/FCF ratio of 112.48, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2025, AroCell AB (publ) maintains a current ratio of 4.69, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025. Return on assets (ROA) is negative at -30.77, reflecting losses generated across the asset base. Inventory turnover of 7.09 indicates how many times AroCell AB (publ) sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on June 23, 2025, AroCell AB (publ)'s stock has gained approximately 25.50% over the past 52 weeks. The 50-day moving average sits at 0.56, while the 200-day moving average is 0.52.

Over the twelve months ended March 31, 2025, AroCell AB (publ) posted a gross margin of 20.61, reflecting its pricing power and cost economics. The operating margin of -75.11 and net profit margin of -73.77 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield stands at 0.57, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

AroCell AB (publ)'s most recent stock split took place on January 25, 2022 with a 500:509 split ratio.

As of March 31, 2025, AroCell AB (publ) has an Altman Z-Score of -2.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.